Clinical Trials Logo

Communicable Diseases clinical trials

View clinical trials related to Communicable Diseases.

Filter by:

NCT ID: NCT02400086 Completed - Clinical trials for Respiratory Tract Infections

Bacterial Colonization in Tracheostomized Patients With Neurological or Neuromuscular Disease

ECOTRACH
Start date: February 2015
Phase:
Study type: Observational

Patients with neurological or neuromuscular diseases may need a long-term tracheostomy to improve their respiratory function. Bacterial flora and bacterial drug resistance in the respiratory tract have never been studied until then for this type of patient in spite of their frequent hospital stay, their regular exposition to antibiotics and their susceptibility to swallowing disorders due to their pathology. This study is based on a single tracheal aspirate within the 48 first hours of the patient stay for a ventilation check up beside any infectious context to describe the basal bacterial respiratory flora.

NCT ID: NCT02398968 Completed - Clinical trials for Iron Deficiency Anemia

Iron Supplementation Outcome on Recurrent Upper Respiratory Tract Infections in 6-15 Years Old Egyptian School Children

Start date: August 2013
Phase: N/A
Study type: Interventional

Recurrent upper respiratory infections ( RURTIs) are common in school aged children. An adequate iron status might reduce their prevalence. The aim of the study is to assess the percentage and type of RURTIs in Egyptian school children, assessing the percentage of iron deficiency anemia (IDA) and the effect of iron supplementation on the recurrence and severity of upper respiratory tract infections .

NCT ID: NCT02395159 Completed - Infections Clinical Trials

Reduction of Groin Wound Infections After Vascular Surgery by Using an Incision Management System (IMS)

IMS
Start date: July 2015
Phase: N/A
Study type: Interventional

Comparison of the Prevena™ IMS with the standard wound management method of sterile plaster in vascular surgery patients.

NCT ID: NCT02388516 Completed - Clinical trials for Upper Respiratory Tract Infections

Maternal Vitamin D for Acute Respiratory Infections in Infancy

MDARI
Start date: December 2014
Phase: Phase 3
Study type: Interventional

There is a growing body of data suggesting that vitamin D modulates the host's immune response to acute respiratory infection (ARI). The primary aim of this study is to determine whether maternal vitamin D3 supplementation versus placebo decreases the incidence rate of microbiologically confirmed viral-associated ARI among infants in Dhaka, Bangladesh. Secondary outcomes include: A) incidence of ARI associated with specific major pathogens, B) incidence of clinical ARI (without the need for positive microbiology), and C) quantitative density of pneumococcal carriage. Infants will be followed from birth until 6 months of life. Among infants who meet at least one of the specific case definitions for ARI (see 'Detailed Description' section), nasal swab specimens will be collected. Respiratory samples will be analyzed by real-time polymerase chain reaction (qPCR) to identify a 7-virus panel (influenza A and B, respiratory syncytial virus, human metapneumovirus, adenovirus, and parainfluenza types 1, 2, and 3) plus quantitative density of S. pneumonia.

NCT ID: NCT02387983 Completed - Fungal Infection Clinical Trials

Pharmacokinetics and Safety of Oral Posaconazole (MK-5592)Tablets in Chinese Participants at High Risk for Invasive Fungal Infections (MK-5592-117)

Start date: May 6, 2015
Phase: Phase 1
Study type: Interventional

The purpose of this study is to evaluate the pharmacokinetics and safety of oral posaconazole tablets in Chinese participants at high risk for invasive fungal infections. Neutropenic participants undergoing chemotherapy for acute myelogenous leukemia or myelodysplastic syndromes will be enrolled in the study.

NCT ID: NCT02387606 Completed - Clinical trials for Respiratory Syncytial Virus Infections

Study to Evaluate Antiviral Activity, Safety, and Pharmacokinetics of Repeated Doses of Orally Administered JNJ 53718678 Against Respiratory Syncytial Virus Infection.

Start date: May 7, 2015
Phase: Phase 2
Study type: Interventional

The purpose of this study is to evaluate the antiviral effect of repeated oral dosing of JNJ 53718678 compared to placebo in healthy adult participants infected through inoculation with respiratory syncytial virus (RSV)-A Memphis 37b virus.

NCT ID: NCT02386514 Completed - Infection Clinical Trials

Emergency Department, Rapid Assessment for Sexually Transmitted Infection

ED-RASTI
Start date: June 2016
Phase: N/A
Study type: Observational

To evaluate if a rapid urine Nucleic Acid Amplification Testing (NAAT) is non-inferior to the traditional swab NAAT for gonorrhea and chlamydia when performed in the Emergency Department.

NCT ID: NCT02385708 Completed - Clinical trials for Surgical Site Infection

Use of 2% Chlorhexidine Cloths Reduce Surgical Site Infections

Start date: August 2015
Phase: N/A
Study type: Interventional

Use of 2% chlorhexidine gluconate cloths pre-operatively and daily post-operatively jaw line to toes will decrease surgical site infections (SSI) by 30% when compared to patients who receive routine standard of care (use of chlorhexidine cloths night before surgery and morning of surgery).

NCT ID: NCT02384395 Completed - HIV Clinical Trials

Safety and Efficacy of Fixed Dose Combination Dolutegravir/Abacavir/Lamivudine FDC Initiated During Acute HIV Infection

PHI-05
Start date: September 2015
Phase: N/A
Study type: Interventional

This is a multicenter, single arm, 96-week open-label study of the safety and virologic efficacy of fixed dose combination Dolutegravir/Lamivudine/Abacavir (DTG/3TC/ABC FDC) initiated during acute HIV infection (AHI).

NCT ID: NCT02378961 Completed - Clinical trials for Hepatitis C Virus Infection

Safety and Efficacy of Voxilaprevir Plus Sofosbuvir/Velpatasvir Fixed Dose Combination in Adults With Chronic Non-Genotype 1 HCV Infection

Start date: February 16, 2015
Phase: Phase 2
Study type: Interventional

The primary objectives of the study are to evaluate the safety, tolerability, and efficacy of voxilaprevir (VOX) plus sofosbuvir/velpatasvir (SOF/VEL) fixed dose combination (FDC) in adults with chronic non genotype 1 hepatitis C virus (HCV) infection.